Summary
Chairpersons: Prof. Ewa Jankowska (Heart Failure Association of the ESC), Prof. John McMurray (ESC),
Dr. Claudia Kaiser-Albers (MSD), Dr. Tomas Andersson (AstraZeneca).
Objectives of the workshop
- Discuss and align challenges and opportunities facing the development of new medicines and technologies for heart failure.
- Identify hurdles in implementation and approaches to overcome them.
- Define what needs to be modified/changed/optimised in the development and implementation of the new guidelines.
Session 1
Session 2
Session 3
Patient 1
Patient 2
Programme
|
DAY 1 – 16 September 2021 - 14:00-17:15 CEST The evidence and the implementation of ESC Clinical Practice Guidelines Chaired by Prof. E. Jankowska and Dr. T. Andersson |
|
|---|---|
|
16 September 14:00 - 14:10 |
Introduction: Goals of the CRT and objectives of the workshop Dr. C. Kaiser-Albers |
|
SESSION 1 - ESC Clinical Practice Guidelines 2021 - Where do we stand and what evidence do we stand on? Moderated by Prof. E. Jankowska and Dr. T. Andersson |
|
|
14:10 - 14:25 |
Presentation of the new Guidelines Prof. M. Metra (IT) and Prof. T. McDonagh (UK) |
|
14:25 - 14:35 |
The concept of a universal definition of heart failure Why and what it means in practice A joint venture of HFA/HFSA/JHFS societies Prof. B. Bozkurt (US) |
|
14:35 - 14:55 |
Reflections on the Guidelines and how they are Implemented Prof. J. McMurray and Prof. W. Mullens (BE) |
|
14:55 - 15:05 |
How do we improve implementation of evidence in practice? Dr. O. Chioncel (RO) |
|
15:05 - 15:45 |
Panel discussion including academia, industry, payers, regulatory, patients All |
|
15:45 - 16:00 |
Break |
|
16:00 - 17:00 |
Breakout Sessions : Moderated by appointed experts and discussants |
|
17:00 – 17:15 |
Summary of pitches - Wrap-up Day 1 - Outlook on Day 2 Prof. E. Jankowska and Dr. C. Kaiser-Albers |
|
DAY 2 – 17 September 2021 - 14:00-17:30 CEST Optimising outcomes in heart failure Chaired by Prof. J. McMurray and Dr. C. Kaiser-Albers |
|
|---|---|
|
14:00 - 14:15 |
Summary of Day 1 - Viewpoints from the Breakout Sessions Dr. C. Kaiser-Albers and Dr. T. Andersson |
|
SESSION 2 - Optimising outcomes in heart failure: what else? Moderated by Prof. J. Mc Murray and Dr. C. Kaiser-Albers |
|
|
14:15 - 14:25 |
What do we mean by “HFpEF” in 2021 and how should it be treated? Prof. S. Solomon (US) |
|
14:25 - 14:35 |
Should we bother about the treatment advances: Quality of life and functional capacity? Prof. A. Coats (UK) |
|
14:35 - 14:45 |
How do we measure QoL and assess functional capacity? Dr. L. Hill (UK) |
|
14:45 - 14:55 |
Patient perspective: What matters to me? |
|
14:55 - 15:05 |
How can regulators and payers contribute to optimise outcomes? Dr. C. Mittmann (DE) |
|
15:05 - 15:15 |
How can regulators and payers contribute to optimise outcomes? Prof. U. Siebert (AT) |
|
15:15 - 15:45 |
Panel / Moderated discussion with panelists and experts representing a geographical diversity |
|
15:45 - 16:00 |
Break |
|
SESSION 3 - Going digital – Will it shake everything up? Moderated by Prof. M. Cowie and Prof. A. Goncalves (Philips) |
|
|
16:00 - 17:30 |
Quick perspectives: |
|
16:00 - 16:10 |
Will digital tools help patients manage their disease better? Lifestyle, treatment and awareness of disease fluctuations Prof. M. Volterrani (IT) |
|
16:10 - 16:20 |
Can we capture clinical status, activity levels and treatment adherence remotely? Prof. F. Koehler (DE) |
|
16:20 - 16:30 |
Education, implementation, adherence, monitoring and outcomes - The digital future of cardiology Dr. R. Califf (US) |
|
16:30 - 16:40 |
Digital clinical trials – Patient enrolment, monitoring and collection of follow-up data Prof. L. Lund (SE) |
|
16:40 - 17:15 |
Panel Discussion - Could we have a common digital platform to deliver routine care and conduct clinical trials? |
|
17:15 - 17:30 |
Key take-home messages / Recommendations for preparation of the publication Chairpersons |
Our mission: To reduce the burden of cardiovascular disease.